SIRPA and neoplasm: CD47’s established role in tumor immune evasion may represent a targetable vulnerability in personalized therapeutic approaches and has prompted the development of an anti-CD47 monoclonal antibody, which blocks the CD47-SIRPα interaction to promote phagocytosis of tumor cells.